[
  {
    "ts": null,
    "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
    "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
    "url": "https://finnhub.io/api/news?id=201eee4a76dd71d58f6c2edd6ba072051a30d268602353be94fef49990373258",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136740,
      "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
      "id": 138345548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
      "url": "https://finnhub.io/api/news?id=201eee4a76dd71d58f6c2edd6ba072051a30d268602353be94fef49990373258"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says",
    "summary": "Johnson & Johnson's (JNJ) solid financial position and robust fundamentals will likely mitigate the",
    "url": "https://finnhub.io/api/news?id=c22d6340e34689f941ab8e7b96d55bbed4f5c2c08f5513cac8f46e188dc13092",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770135536,
      "headline": "Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says",
      "id": 138344078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson's (JNJ) solid financial position and robust fundamentals will likely mitigate the",
      "url": "https://finnhub.io/api/news?id=c22d6340e34689f941ab8e7b96d55bbed4f5c2c08f5513cac8f46e188dc13092"
    }
  },
  {
    "ts": null,
    "headline": "5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates",
    "summary": "Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.",
    "url": "https://finnhub.io/api/news?id=db8188f3e065af95a59b8cd62d2a5b6c21cadbc7a3e799cfea623c3fc7e72d15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130800,
      "headline": "5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates",
      "id": 138344079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.",
      "url": "https://finnhub.io/api/news?id=db8188f3e065af95a59b8cd62d2a5b6c21cadbc7a3e799cfea623c3fc7e72d15"
    }
  },
  {
    "ts": null,
    "headline": "Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek",
    "summary": "SAN FRANCISCO, February 03, 2026--Toptal, the world’s largest fully remote workforce, has been ranked the #1 most reliable professional services company in America on the America’s Most Reliable Companies 2026 list by Newsweek and Statista. The list ranks top US companies based on trust, dependability, and consistent performance in their industry.",
    "url": "https://finnhub.io/api/news?id=2d6bf3673034a81679a1c101beede7554d629e9348066f65bfd802630813ea06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130800,
      "headline": "Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek",
      "id": 138342467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, February 03, 2026--Toptal, the world’s largest fully remote workforce, has been ranked the #1 most reliable professional services company in America on the America’s Most Reliable Companies 2026 list by Newsweek and Statista. The list ranks top US companies based on trust, dependability, and consistent performance in their industry.",
      "url": "https://finnhub.io/api/news?id=2d6bf3673034a81679a1c101beede7554d629e9348066f65bfd802630813ea06"
    }
  },
  {
    "ts": null,
    "headline": "DGRO: This Diversified Dividend Growth Fund Is Getting Pricey",
    "summary": "DGRO: This Diversified Dividend Growth Fund Is Getting Pricey",
    "url": "https://finnhub.io/api/news?id=ad6eb402da4430178f476b94b861881a01e39777047e6df8fc51a87c56492227",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770121287,
      "headline": "DGRO: This Diversified Dividend Growth Fund Is Getting Pricey",
      "id": 138343719,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ad6eb402da4430178f476b94b861881a01e39777047e6df8fc51a87c56492227"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "url": "https://finnhub.io/api/news?id=1fab5cfafb6210e5e1cf4b0b6623877b065cc36e8c5967b2d79a54c6c3eb0683",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119940,
      "headline": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
      "id": 138341606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
      "url": "https://finnhub.io/api/news?id=1fab5cfafb6210e5e1cf4b0b6623877b065cc36e8c5967b2d79a54c6c3eb0683"
    }
  },
  {
    "ts": null,
    "headline": "BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher […]",
    "url": "https://finnhub.io/api/news?id=026fbe30638b84d84655b312a471d185f43b3cb707e340c71adba1848e6e4d1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770111256,
      "headline": "BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why",
      "id": 138340023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best long term low volatility stocks to invest in. On January 30, BofA lifted the price target on Johnson & Johnson (NYSE:JNJ) to $227 from $221 while maintaining a Neutral rating on the shares. The firm told investors that the increased price target points towards a higher […]",
      "url": "https://finnhub.io/api/news?id=026fbe30638b84d84655b312a471d185f43b3cb707e340c71adba1848e6e4d1a"
    }
  },
  {
    "ts": null,
    "headline": "ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story",
    "summary": "New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...",
    "url": "https://finnhub.io/api/news?id=e4f50077247768353674df3b367b850938b4c20dcc30ab145f171b80eb8f61c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770084609,
      "headline": "ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story",
      "id": 138338517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "New clinical data supports ERLEADA for metastatic castration sensitive prostate cancer, reinforcing its role in current treatment practice. DARZALEX FASPRO received expanded FDA approval for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. These updates reflect further development in Johnson & Johnson's oncology portfolio under ticker NYSE:JNJ. For investors tracking NYSE:JNJ, these oncology updates come as the stock trades around $230.75, with a...",
      "url": "https://finnhub.io/api/news?id=e4f50077247768353674df3b367b850938b4c20dcc30ab145f171b80eb8f61c2"
    }
  }
]